MedTrace Logo

Relative Bioavailability Study of CX2101A for the Treatment of COVID-19

NCT06864182 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-03-14

No results posted yet for this study

Summary

The study comprises three parts: single ascending dose (SAD) studies of CX2101A tablets at 40 mg, 100 mg, and 160 mg; a relative bioavailability (BA) study comparing single-dose administration of 100 mg CX2101A tablets and enteric-coated tablets; and a multiple ascending dose (MAD) study of CX2101A tablets. The BA study (100 mg) is integrated into the SAD study(Nested within the SAD protocol to optimize resource utilization).

Conditions

Interventions

DRUG

CX2101A tablet

CX2101A tablet

DRUG

CX2101A placebo tablet

CX2101A placebo tablet

DRUG

CX2101A enteric-coated tablet

CX2101A enteric-coated tablet

DRUG

CX2101A placebo enteric-coated tablet

CX2101A placebo enteric-coated tablet

Sponsors & Collaborators

  • Heronova Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-03-21
Primary Completion
2024-05-25
Completion
2024-05-25

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06864182 on ClinicalTrials.gov